OREANDA-NEWS. The Board of Directors of Ranbaxy Laboratories Limited, at their meeting held, took on record the audited results for the Quarter and Year ended Dec 31, 2012  (“Q4’12” and “CY’12” respectively) under Indian GAAP.

Financial Performance for the quarter ended Dec 31, 2012 (Q4’12)
* Consolidated sales were Rs.26,708 Mn [Q4’11: Sales Rs.37,520]. While absolute sales declined over the corresponding quarter as Q4’11 sales included a large contribution from exclusivities, on a like-to-like basis sales registered double digit growth.
* Earnings before Interest, Tax, Depreciation & Amortization (EBITDA) without considering exceptional items, was Rs.528 Mn. Net Profit was a loss of Rs.4,924 Mn.
* Profitability for Q4’12 was primarily impacted by the voluntary recall which impacted the quarter by Rs.1,860 Mn and mark to market (MTM) loss of Rs.2,619 Mn on long term derivative contracts and foreign currency loans owing to a weaker rupee.

Financial Performance for the Year ended Dec 31, 2012 (CY’12)
* Consolidated sales were Rs.122,529 Mn [CY 11: Sales Rs.99,700 Mn] Sales growth of 23% in rupee terms over the corresponding year.
* EBITDA without considering exceptional items was 15% of Sales at Rs.18,227 Mn  [CY 11: EBITDA Rs.16,040 Mn].
* Profit After Tax (PAT) was Rs.9,228 Mn [CY 11: Loss of Rs.28,998 Mn]
* PAT for CY’12 was 8% of sales after incorporating one time charges of Rs.1,860 Mn and Rs.1,652 Mn on account of recall and forex MTM mentioned earlier. Base business profitability, excluding forex gains and one-time gains/ losses improved over the previous year.